The efficacy of an imidacloprid/moxidectin combination against naturally acquired Sarcoptes scabiei infestations on dogs

The study was undertaken to evaluate and compare the efficacy of an imidacloprid (10% w/v)/moxidectin (2.5% w/v) combination (Advocate Bayer HealthCare, Animal Health) with that of selamectin for the treatment of Sarcoptes scabiei on dogs. Thirty naturally infested dogs, of which one was later withdrawn because of distemper, were allocated to two equal groups and individually housed. The dogs in each group were treated twice, four weeks apart, with either the combination product (0.1 mL/kg body weight) or with selamectin (0.05 mL/kg body weight) administered topically. Skin scrapings were made every 14 days over a period of 50 to 64 days after the first treatment to quantify mite numbers. Clinical signs and the extent of sarcoptic lesions were assessed on each dog when skin scrapings were made. Efficacy was based on the presence or absence of mites, supported by clinical signs associated with canine sarcoptic mange. From Day 22 and onwards no Sarcoptes mites were found in the skin scrapings of any of the treated dogs. Treatment with the imidacloprid/moxidectin formulation or with selamectin was highly effective against Sarcoptes scabiei and resulted in an almost complete resolution of clinical signs within 50 to 64 days after the initial treatment.